Sernova Corp. (SEOVF)
USD 0.13
(0.32%)
USD 0.13
(0.32%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -38.99 Million CAD | -59.69% |
| 2022 | -24.42 Million CAD | -250.59% |
| 2021 | -6.96 Million CAD | -30.9% |
| 2020 | -5.32 Million CAD | -34.0% |
| 2019 | -3.97 Million CAD | -7.37% |
| 2018 | -3.69 Million CAD | -40.13% |
| 2017 | -2.63 Million CAD | -5.6% |
| 2016 | -2.49 Million CAD | 12.58% |
| 2015 | -2.85 Million CAD | -4.13% |
| 2014 | -2.74 Million CAD | -37.1% |
| 2013 | -2 Million CAD | 22.01% |
| 2012 | -2.56 Million CAD | -26.61% |
| 2011 | -2.02 Million CAD | -9.85% |
| 2010 | -1.84 Million CAD | -25.74% |
| 2009 | -1.46 Million CAD | 46.67% |
| 2008 | -2.75 Million CAD | 23.35% |
| 2007 | -3.59 Million CAD | -185.74% |
| 2006 | -1.25 Million CAD | -189.96% |
| 2005 | -433.56 Thousand CAD | -17.7% |
| 2004 | -368.37 Thousand CAD | 48.11% |
| 2003 | -709.85 Thousand CAD | 52.55% |
| 2002 | -1.49 Million CAD | 30.08% |
| 2001 | -2.13 Million CAD | -406.99% |
| 2000 | -422.08 Thousand CAD | -1847.05% |
| 1999 | -21.67 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -9.74 Million CAD | 16.75% |
| 2024 Q2 | -9.94 Million CAD | -2.06% |
| 2024 Q3 | -7.53 Million CAD | 24.2% |
| 2023 Q4 | -11.7 Million CAD | -17.84% |
| 2023 Q3 | -9.93 Million CAD | -6.26% |
| 2023 Q2 | -9.34 Million CAD | -16.61% |
| 2023 Q1 | -8.01 Million CAD | 2.38% |
| 2023 FY | -38.99 Million CAD | -59.69% |
| 2022 Q2 | -4.91 Million CAD | 9.88% |
| 2022 FY | -24.42 Million CAD | -250.59% |
| 2022 Q3 | -5.83 Million CAD | -18.53% |
| 2022 Q4 | -8.21 Million CAD | -40.79% |
| 2022 Q1 | -5.45 Million CAD | -150.95% |
| 2021 Q1 | -1.49 Million CAD | -44.8% |
| 2021 Q4 | -2.17 Million CAD | -33.37% |
| 2021 Q3 | -1.63 Million CAD | 2.16% |
| 2021 FY | -6.96 Million CAD | -30.9% |
| 2021 Q2 | -1.66 Million CAD | -11.71% |
| 2020 Q1 | -1.36 Million CAD | 22.59% |
| 2020 Q3 | -1.19 Million CAD | 31.02% |
| 2020 Q4 | -1.03 Million CAD | 13.8% |
| 2020 FY | -5.32 Million CAD | -34.0% |
| 2020 Q2 | -1.73 Million CAD | -27.26% |
| 2019 Q1 | -723.75 Thousand CAD | 13.26% |
| 2019 FY | -3.97 Million CAD | -7.37% |
| 2019 Q3 | -874.75 Thousand CAD | -42.62% |
| 2019 Q4 | -1.75 Million CAD | -101.13% |
| 2019 Q2 | -613.35 Thousand CAD | 15.25% |
| 2018 FY | -3.69 Million CAD | -40.13% |
| 2018 Q3 | -1.11 Million CAD | -12.69% |
| 2018 Q4 | -834.36 Thousand CAD | 24.94% |
| 2018 Q1 | -766.35 Thousand CAD | 21.62% |
| 2018 Q2 | -986.35 Thousand CAD | -28.71% |
| 2017 Q1 | -317.52 Thousand CAD | -90.93% |
| 2017 FY | -2.63 Million CAD | -5.6% |
| 2017 Q4 | -977.73 Thousand CAD | -38.53% |
| 2017 Q3 | -705.79 Thousand CAD | -10.55% |
| 2017 Q2 | -638.43 Thousand CAD | -101.07% |
| 2016 Q3 | -964.94 Thousand CAD | -39.46% |
| 2016 Q1 | -676.45 Thousand CAD | 23.66% |
| 2016 Q2 | -691.91 Thousand CAD | -2.29% |
| 2016 Q4 | -166.3 Thousand CAD | 82.77% |
| 2016 FY | -2.49 Million CAD | 12.58% |
| 2015 Q2 | -676.21 Thousand CAD | -7.29% |
| 2015 FY | -2.85 Million CAD | -4.13% |
| 2015 Q4 | -886.11 Thousand CAD | -32.88% |
| 2015 Q1 | -630.29 Thousand CAD | 7.06% |
| 2015 Q3 | -666.85 Thousand CAD | 1.38% |
| 2014 Q1 | -594.1 Thousand CAD | -10.54% |
| 2014 Q2 | -747.93 Thousand CAD | -25.89% |
| 2014 Q3 | -725.83 Thousand CAD | 2.95% |
| 2014 FY | -2.74 Million CAD | -37.1% |
| 2014 Q4 | -678.18 Thousand CAD | 6.57% |
| 2013 Q4 | -537.44 Thousand CAD | -40.55% |
| 2013 FY | -2 Million CAD | 22.01% |
| 2013 Q2 | -551.7 Thousand CAD | -3.82% |
| 2013 Q3 | -382.39 Thousand CAD | 30.69% |
| 2013 Q1 | -531.38 Thousand CAD | 22.96% |
| 2012 Q1 | -625.83 Thousand CAD | -28.29% |
| 2012 Q2 | -677.97 Thousand CAD | -8.33% |
| 2012 FY | -2.56 Million CAD | -26.61% |
| 2012 Q4 | -689.73 Thousand CAD | -20.06% |
| 2012 Q3 | -574.48 Thousand CAD | 15.26% |
| 2011 FY | -2.02 Million CAD | -9.85% |
| 2011 Q1 | -569.77 Thousand CAD | -15.36% |
| 2011 Q2 | -570.28 Thousand CAD | -0.09% |
| 2011 Q3 | -423.22 Thousand CAD | 25.79% |
| 2011 Q4 | -487.81 Thousand CAD | -15.26% |
| 2010 Q2 | -425.6 Thousand CAD | 5.07% |
| 2010 Q3 | -478.49 Thousand CAD | -12.43% |
| 2010 Q1 | -448.36 Thousand CAD | 3.24% |
| 2010 FY | -1.84 Million CAD | -25.74% |
| 2010 Q4 | -493.9 Thousand CAD | -3.22% |
| 2009 Q3 | -342.67 Thousand CAD | 10.78% |
| 2009 Q2 | -384.08 Thousand CAD | -38.05% |
| 2009 Q1 | -278.22 Thousand CAD | 50.67% |
| 2009 FY | -1.46 Million CAD | 46.67% |
| 2009 Q4 | -463.37 Thousand CAD | -35.22% |
| 2008 Q1 | -623.17 Thousand CAD | 37.91% |
| 2008 Q4 | -564.06 Thousand CAD | -15.35% |
| 2008 Q3 | -488.99 Thousand CAD | 54.61% |
| 2008 Q2 | -1.07 Million CAD | -72.86% |
| 2008 FY | -2.75 Million CAD | 23.35% |
| 2007 Q3 | -1.05 Million CAD | 5.69% |
| 2007 Q2 | -1.11 Million CAD | -170.85% |
| 2007 Q1 | -413.3 Thousand CAD | -645.44% |
| 2007 Q4 | -1 Million CAD | 4.93% |
| 2007 FY | -3.59 Million CAD | -185.74% |
| 2006 Q3 | -107.38 Thousand CAD | 90.47% |
| 2006 Q2 | -1.12 Million CAD | -1046.42% |
| 2006 Q1 | -98.32 Thousand CAD | 16.07% |
| 2006 Q4 | 75.77 Thousand CAD | 170.56% |
| 2006 FY | -1.25 Million CAD | -189.96% |
| 2005 FY | -433.56 Thousand CAD | -17.7% |
| 2005 Q3 | -77.42 Thousand CAD | 51.07% |
| 2005 Q4 | -117.15 Thousand CAD | -51.32% |
| 2005 Q1 | -80.73 Thousand CAD | -210.26% |
| 2005 Q2 | -158.24 Thousand CAD | -96.0% |
| 2004 Q4 | 73.22 Thousand CAD | 175.53% |
| 2004 Q2 | -164.54 Thousand CAD | 8.65% |
| 2004 FY | -368.37 Thousand CAD | 48.11% |
| 2004 Q3 | -96.94 Thousand CAD | 41.08% |
| 2004 Q1 | -180.11 Thousand CAD | -86.09% |
| 2003 Q3 | -85.45 Thousand CAD | 65.45% |
| 2003 FY | -709.85 Thousand CAD | 52.55% |
| 2003 Q2 | -247.31 Thousand CAD | 11.76% |
| 2003 Q1 | -280.29 Thousand CAD | -16.04% |
| 2003 Q4 | -96.78 Thousand CAD | -13.26% |
| 2002 Q2 | -467.51 Thousand CAD | -1.14% |
| 2002 Q1 | -462.24 Thousand CAD | 0.0% |
| 2002 Q4 | -241.55 Thousand CAD | 25.64% |
| 2002 FY | -1.49 Million CAD | 30.08% |
| 2002 Q3 | -324.83 Thousand CAD | 30.52% |
| 2001 FY | -2.13 Million CAD | -406.99% |
| 2000 FY | -422.08 Thousand CAD | -1847.05% |
| 1999 FY | -21.67 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -3.81 Million USD | -921.145% |
| Skye Bioscience, Inc. | -37.64 Million USD | -3.593% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 159.874% |
| Nascent Biotech, Inc. | -2.08 Million USD | -1767.982% |
| Qrons Inc. | -789.34 Thousand USD | -4840.479% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -9286.159% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -458.477% |
| BioStem Technologies, Inc. | -8.48 Million USD | -359.715% |
| Regen BioPharma, Inc. | 1.02 Million USD | 3910.182% |
| CSL Limited | 2.64 Billion USD | 101.476% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 37.703% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 173.609% |
| Rebus Holdings, Inc. | -1.02 Million USD | -3723.286% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -2820.22% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -6066.523% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -145.709% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 47.978% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -493.018% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -14163.802% |
| SQZ Biotechnologies Company | -79.46 Million USD | 50.924% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -1248.278% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -2042.099% |
| Mesoblast Limited | -87.95 Million USD | 55.662% |
| Marizyme, Inc. | -65.34 Million USD | 40.322% |
| Genus plc | 7.9 Million USD | 593.639% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -258.047% |
| Pharming Group N.V. | -10.54 Million USD | -269.715% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -1697.275% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -951.08% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -340.949% |
| ContraFect Corporation | -65.15 Million USD | 40.145% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -698.138% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -2157.513% |
| IMV Inc. | -36.48 Million USD | -6.884% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -383.859% |
| MultiCell Technologies, Inc. | -380.07 USD | -10260515.15% |
| ONE Bio Corp. | 8.67 Million USD | 549.456% |
| Accustem Sciences Inc. | -3.74 Million USD | -940.928% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 24.558% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -2977.616% |
| Q BioMed Inc. | -2.05 Million USD | -1800.378% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -944.67% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -1537.953% |
| Biomind Labs Inc. | -1.21 Million USD | -3111.472% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 34.705% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -1157.267% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -393.446% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -1900.643% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -260300.107% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -570.377% |
| GB Sciences, Inc. | -1.36 Million USD | -2763.933% |
| Alpha Cognition Inc. | -13.77 Million USD | -183.154% |
| HST Global, Inc. | -146.21 Thousand USD | -26572.266% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -2122.371% |
| Halberd Corporation | -79.67 Thousand USD | -48845.128% |
| Enzolytics Inc. | -2.17 Million USD | -1691.48% |
| Agentix Corp. | -1.37 Million USD | -2737.812% |
| Resverlogix Corp. | -3.61 Million USD | -980.264% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -1129.649% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 86.783% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 39893.388% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 663.174% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -881.565% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -1188.691% |
| AVAX Technologies, Inc. | -6.41 Million USD | -508.04% |
| Zenith Capital Corp. | -10.59 Million USD | -268.04% |
| Genscript Biotech Corporation | -95.47 Million USD | 59.155% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -167689.003% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -840.62% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -64422.049% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -1844.902% |
| Kadimastem Ltd | -3.3 Million USD | -1079.1% |
| Helix BioMedix, Inc. | -1.05 Million USD | -3592.748% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -8735.582% |
| LadRx Corporation | 400.44 Thousand USD | 9838.595% |
| Cell Source, Inc. | -5.32 Million USD | -632.869% |
| Regen BioPharma, Inc. | 1.02 Million USD | 3910.182% |
| NovAccess Global Inc. | -4.76 Million USD | -717.697% |
| Affymax, Inc. | -14.42 Million USD | -170.366% |
| Itoco Inc. | -1.86 Million USD | -1986.55% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -777.821% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -2236.58% |
| Mobile Lads Corp. | -2.26 Million USD | -1623.044% |
| CytoDyn Inc. | -49.84 Million USD | 21.756% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -49243.338% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -16994.653% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -4041.935% |
| SYBLEU INC | -180.3 Thousand USD | -21528.76% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -2318.095% |
| International Stem Cell Corporation | -131 Thousand USD | -29669.099% |
| Bioxytran, Inc. | -4.28 Million USD | -811.157% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -71755.69% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -1441.253% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 18.877% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -1744.727% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -4894.003% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -1130.982% |
| Neutra Corp. | -233.46 Thousand USD | -16603.797% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -92.191% |
| PureTech Health plc | -65.69 Million USD | 40.64% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -83.375% |
| IXICO plc | -1.17 Million USD | -3210.486% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -292.843% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 31.737% |
| CSL Limited | 2.64 Billion USD | 101.476% |
| Cellectis S.A. | -103.17 Million USD | 62.202% |